Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with Keytruda (pembrolizumab; Merck & Co.) were presented at ASCO 2017; preliminary results from the ongoing Phase I/II ECHO-204 trial of epacadostat plus Opdivo (nivolumab; Bristol-Myers Squibb [BMS]) in patients with solid tumours, including HNSCC, were presented at ASCO 2017; Merck & Co. announced that the Phase III KEYNOTE-040 trial of Keytruda in previously treated patients with recurrent or metastatic HNSCC failed to meet its primary endpoint of overall survival (OS).
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved